Ticker
AEZS

Price
3.74
Stock movement down
-0.08 (-2.09%)
Company name
Aeterna Zentaris Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Markedsværdi
18.16M
Ent værdi
-18.47M
Pris/omsætning
2.74
Pris/bog
0.37
Udbytte afkast
-
Udbyttevækst
-
Vekst år
-
FCF-udbetaling
-
Efterfølgende P/E
-
Fremtidig P/E
-
PEG
-
EPS-vekst
-
1 års afkast
-57.26%
3 års afkast
-49.62%
5 års afkast
-40.99%
10 års afkast
-53.08%
Senest opdateret: 2023-02-06

UDBYTTE

AEZS betaler ikke udbytte

VÆRDIANSÆTTELSE

Værdiansættelsesforhold

Loading...
Værdiansættelsesforhold-data
Efterfølgende P/E-
Pris til OCF-
Pris til FCF-
Pris til EBITDA-
EV i forhold til EBITDA-

Værdiansættelse (salg/bogført værdi)

Loading...
Værdiansættelse (salg/bogført værdi)-data
Pris til omsætning2.74
Pris til egenkapital0.37
EV i forhold til salg-2.79

ØKONOMI

Pr. aktie

Loading...
Data pr. aktie
Aktuelt antal aktier4.86M
EPS (TTM)-2.77
FCF pr. aktie (TTM)-2.65

Resultatopgørelse

Loading...
Resultatopgørelse-data
Omsætning (TTM)6.63M
Bruttofortjeneste (TTM)6.50M
Driftsindkomst (TTM)-14.67M
Nettoindkomst (TTM)-13.46M
EPS (TTM)-2.77
EPS (1 år frem)-3.68

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)98.13%
Driftsmargin (TTM)-221.38%
Fortjenstmargin (TTM)-203.11%

Balance

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
Kontanter53.82M
Nettotilgodehavender2.08M
Omsætningsaktiver i alt58.61M
Goodwill7.03M
Immaterielle aktiver537.00K
Ejendomme, anlæg og udstyr0.00
Sum aktiver66.61M
Kreditor720.00K
Kortfristet/nuværende langsigtet gæld89.00K
Summen af kortfristede forpligtelser5.97M
Sum gæld17.19M
Aktionærernes egenkapital49.42M
Materielle nettoaktiver41.85M

Likviditet

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
Likviditet fra driften (TTM)-12.67M
Investeringsudgifter (TTM)181.00K
Fri pengestrøm (TTM)-12.85M
Udbetalt udbytte (TTM)0.00

Finansiel indkomst

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
Egenkapitalafkast-27.24%
Afkast af aktiver-20.21%
Afkast af investeret kapital-27.20%
Kontant afkast af investeret kapital-25.96%

INFORMATION OM AKTIER

Aktiediagram

Loading...
Aktiekurs-data
Åbning3.75
Daglig høj3.82
Daglig lav3.74
Daglig volumen23K
Højeste gennem alle tider94881.00
1 års analytiker estimat28.00
Beta1.66
EPS (TTM)-2.77
Udbytte pr. aktie-
Ex-div dato-
Næste dato for resultatpræsentation27 Mar 2023

Nedsidepotensial

Loading...
Nedsidepotensial-data
AEZSS&P500
Nuværende prisfald fra top notering-100.00%-14.21%
Højeste prisfald-100.00%-56.47%
Højeste efterår dato29 Dec 20229 Mar 2009
Gennemsnitlig fald fra toppen-79.67%-11.49%
Gennemsnitlig tid til nyt højdepunkt937 days13 days
Maks. tid til nyt højdepunkt5599 days1805 days
OPLYSNINGER OM VIRKSOMHEDEN
AEZS (Aeterna Zentaris Inc) company logo
Markedsværdi
18.16M
Markedsværdi kategori
Small-cap
Beskrivelse
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and to develop human 3D intestinal tissue models to study infection biology; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd., Novo Nordisk Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.
Personale
0
Investor relationer
-
SEC-indsendelser
Adm. direktør
Klaus Paulini
Land
USA
By
Charleston
Aktietype
Common stock
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...
FORSTÅ FORRETNINGEN
Loading...
NYHEDER OM VIRKSOMHEDEN
Alle nyhederPressemeddelelser
Here is how Aeterna Zentaris (AEZS) and Idexx Laboratories (IDXX) have performed compared to their sector so far this year.
7. februar 2023
Aeterna Zentaris Inc (NASDAQ: AEZS) has decided to streamline development programs by discontinuing its early-stage vaccine programs. The company worked on evaluating administration routes, dosing, an...
17. januar 2023
Aeterna Zentaris focused on accelerating recruitment for ongoing DETECT trial and efforts to partner rights to Macrilen™ in the U.S. and CanadaCompany continues to build growing body of data across it...
17. januar 2023
JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor 2023 Companies to Watch Event, January 17-19, 2023.
11. januar 2023
Live video webcast on Thursday, January 19th at 3:00 PM ET TORONTO, ONTARIO, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialt...
10. januar 2023
Aeterna Zentaris (AEZS) delivered earnings and revenue surprises of -2.94% and 38.81%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
3. november 2022
– Company ended the quarter with $53.8 million in cash – Driving continued progress across diversified pre-clinical and clinical development pipeline TORONTO, ONTARIO, Nov. 03, 2022 (GLOBE NEWSWIRE) -...
3. november 2022
– Company plans to prioritize efforts to identify new strategic development and commercialization partner – Company is in a strong position that enables it to continue the ongoing pivotal Phase 3 stud...
29. august 2022
– Company ended the quarter with $58.2 million in cash – Driving continued progress across diversified pre-clinical and clinical development pipeline TORONTO, ONTARIO, Aug. 03, 2022 (GLOBE NEWSWIRE) -...
3. august 2022
CytomX Therapeutics (CTMX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
28. juli 2022
Næste side